Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CMPX Compass Therapeutics	$3.49	$2.91	$1.25 ▼ $4.08	$482.60M	1.49	1.40 million shs	702,510 shs
CRVS Corvus Pharmaceuticals	$5.74 +6.1%	$4.52	$2.54 ▼ $10.00	$427.69M	0.42	794,265 shs	557,521 shs
IMAB I-Mab	$4.16 -2.1%	$3.00	$0.60 ▼ $5.90	$339.71M	1.38	965,329 shs	1.40 million shs
SPRO Spero Therapeutics	$2.07 +3.5%	$2.39	$0.51 ▼ $3.22	$116.50M	1.39	1.85 million shs	395,346 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CMPX Compass Therapeutics	+6.40%	+24.64%	+10.09%	+63.08%	+193.28%
CRVS Corvus Pharmaceuticals	-1.64%	+2.27%	+19.69%	+42.37%	+31.95%
IMAB I-Mab	-5.56%	-9.77%	+150.00%	+226.92%	+263.25%
SPRO Spero Therapeutics	+1.01%	+7.53%	-9.09%	-22.48%	+45.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CMPX Compass Therapeutics	2.1703 of 5 stars	3.6	1.0	0.0	2.2	3.3	0.0
CRVS Corvus Pharmaceuticals	3.1976 of 5 stars	3.5	2.0	0.0	3.7	3.3	0.6
IMAB I-Mab	2.9673 of 5 stars	3.5	5.0	0.0	2.7	1.7	0.0
SPRO Spero Therapeutics	4.0369 of 5 stars	3.3	3.0	4.7	3.5	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CMPX Compass Therapeutics	3.10	Buy	$12.89	269.31% Upside
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	161.32% Upside
IMAB I-Mab	3.00	Buy	$7.00	68.27% Upside
SPRO Spero Therapeutics	2.50	Moderate Buy	$5.00	141.55% Upside

Current Analyst Ratings Breakdown

Latest SPRO, CMPX, IMAB, and CRVS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/28/2025	IMAB I-Mab	Loop Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$8.00
8/28/2025	IMAB I-Mab	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/21/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
8/20/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$5.00 ➝ $6.00
8/12/2025	CMPX Compass Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
8/12/2025	CMPX Compass Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$10.00 ➝ $12.00
7/9/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	IMAB I-Mab	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00
7/1/2025	CMPX Compass Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform	$9.00
6/27/2025	IMAB I-Mab	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $5.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CMPX Compass Therapeutics	$850K	567.76	N/A	N/A	$0.67 per share	5.21
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$1.08 per share	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	$2.41 per share	N/A
SPRO Spero Therapeutics	$47.98M	2.43	N/A	N/A	$0.58 per share	3.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CMPX Compass Therapeutics	-$49.38M	-$0.45	N/A	N/A	N/A	N/A	-53.11%	-46.14%	11/11/2025 (Estimated)
CRVS Corvus Pharmaceuticals	-$62.29M	-$1.01	N/A	N/A	N/A	N/A	-28.61%	-18.05%	11/11/2025 (Estimated)
IMAB I-Mab	-$22.23M	N/A	0.00	N/A	N/A	N/A	-19.65%	-18.58%	11/13/2025 (Estimated)
SPRO Spero Therapeutics	-$68.57M	-$0.98	N/A	N/A	N/A	-110.35%	-120.27%	-55.61%	11/13/2025 (Estimated)

Latest SPRO, CMPX, IMAB, and CRVS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	Q2 2025	IMAB I-Mab	-$0.10	-$0.07	+$0.03	-$0.07	N/A	N/A
8/12/2025	Q2 2025	SPRO Spero Therapeutics	-$0.38	-$0.03	+$0.35	-$0.03	$11.00 million	$14.19 million
8/11/2025	Q2 2025	CMPX Compass Therapeutics	-$0.13	-$0.14	-$0.01	-$0.14	N/A	N/A
8/7/2025	Q2 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.10	+$0.03	-$0.10	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMAB I-Mab	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CMPX Compass Therapeutics	N/A	7.66	7.66
CRVS Corvus Pharmaceuticals	N/A	8.91	8.91
IMAB I-Mab	N/A	22.82	22.82
SPRO Spero Therapeutics	N/A	3.97	3.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CMPX Compass Therapeutics	68.43%
CRVS Corvus Pharmaceuticals	46.64%
IMAB I-Mab	38.38%
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
CMPX Compass Therapeutics	29.80%
CRVS Corvus Pharmaceuticals	28.50%
IMAB I-Mab	22.10%
SPRO Spero Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CMPX Compass Therapeutics	20	138.28 million	97.08 million	Not Optionable
CRVS Corvus Pharmaceuticals	30	74.51 million	53.28 million	Optionable
IMAB I-Mab	380	81.66 million	63.61 million	Optionable
SPRO Spero Therapeutics	150	56.28 million	53.18 million	Optionable

SPRO, CMPX, IMAB, and CRVS Headlines

Recent News About These Companies

Anson Funds Management LP Has $5.50 Million Position in Spero Therapeutics, Inc. $SPRO

August 26 at 8:11 AM | marketbeat.com

Spero Therapeutics (NASDAQ:SPRO) Stock Passes Above 200-Day Moving Average - Here's What Happened

August 25, 2025 | marketbeat.com

Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround

August 19, 2025 | zacks.com

Spero Therapeutics (NASDAQ:SPRO) Releases Earnings Results, Beats Expectations By $0.32 EPS

August 14, 2025 | marketbeat.com

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2025 Earnings Call Transcript

August 13, 2025 | insidermonkey.com

Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

August 13, 2025 | finanznachrichten.de

Spero Therapeutics Reports Q2 2025 Results and Trial Success

August 13, 2025 | msn.com

Spero Therapeutics Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

August 12, 2025 | globenewswire.com

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

August 5, 2025 | globenewswire.com

While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership

June 28, 2025 | finance.yahoo.com

Spero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

June 11, 2025 | seekingalpha.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | msn.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | insidermonkey.com

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC

May 30, 2025 | pharmabiz.comP

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr

May 29, 2025 | thepharmaletter.comT

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

May 29, 2025 | msn.com

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

May 29, 2025 | zacks.com

GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars

May 28, 2025 | endpts.comE

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SPRO, CMPX, IMAB, and CRVS Company Descriptions

Compass Therapeutics NASDAQ:CMPX

$3.49 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$3.52 +0.03 (+1.00%)

As of 07:27 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Corvus Pharmaceuticals NASDAQ:CRVS

$5.74 +0.33 (+6.10%)

Closing price 04:00 PM Eastern

Extended Trading

$5.68 -0.06 (-1.05%)

As of 07:44 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

I-Mab NASDAQ:IMAB

$4.16 -0.09 (-2.12%)

Closing price 04:00 PM Eastern

Extended Trading

$4.24 +0.08 (+1.80%)

As of 07:27 PM Eastern

I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

Spero Therapeutics NASDAQ:SPRO

$2.07 +0.07 (+3.50%)

Closing price 04:00 PM Eastern

Extended Trading

$2.08 +0.01 (+0.48%)

As of 07:18 PM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time